Skip to main navigation

Main Menu
About
Science
PRODUCTS
Responsibility
Stories
Newsroom
Partners
Investors
Careers
Amgen Worldwide

All Stories
Responsibility
People and Culture
Science and Innovation
Patients
Leadership
Popular Tags

COVID-19
Supporting Our Staff
Leveraging Our Science
Serving Our Communities

All Stories
Responsibility
People and Culture
Science and Innovation
Patients
Leadership
Popular Tags

COVID-19
Supporting Our Staff
Leveraging Our Science
Serving Our Communities

About
Science
PRODUCTS
Responsibility
Stories
Newsroom
Partners
Investors
Careers

Breadcrumb

Home
Investors
Presentations

Presentations

Investors
News & Events
Financials
Pipeline
Stock
ESG
Resources

Presentations

11.26.2024

MariTide Topline Phase 2 Results 756.1 KB

10.30.2024

Q3 2024 Earnings Presentation 1.3 MB

09.24.2024

Rocatinlimab and UPLIZNA Investor Update Presentation 838.2 KB

08.06.2024

Q2 2024 Earnings Presentation 1.3 MB

05.20.2024

Driving Long-Term Growth: IMDELLTRA™ Approval and Inflammation Update Presentation 2.1 MB

05.02.2024

Q1 2024 Earnings Presentation 1.1 MB

04.10.2024

Chairman and CEO Letter and Amgen Inc. 2023 Annual Report 8.1 MB

02.22.2024

Amgen Rare Disease Presentation 2.6 MB

02.06.2024

Q4 2023 Earnings Presentation 1.7 MB

01.08.2024

42nd Annual J.P. Morgan Healthcare Conference Presentation 1.3 MB

12.07.2023

Amgen Investor Presentation December 2023 1.8 MB

10.31.2023

Q3 2023 Earnings Presentation 1.8 MB

10.24.2023

Hematology/Oncology Update ESMO Presentation 5.7 MB

08.03.2023

Q2 2023 Earnings Presentation 2.3 MB

04.27.2023

Q1 2023 Earnings Presentation 1.8 MB

Navbar w/ text

Investors
News & Events
Financials
Pipeline
Stock
ESG
Resources

Earnings

Show all

Q3 2024

Q3 2024 Amgen Earnings Conference Call
AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Q3 2024 Earnings Presentation 1.3 MB

Data as of:

Minimum 15 minutes delayed. Source: LSEG

Stay Connected With Amgen.

Contact Us Sitemap Privacy Statement Terms of Use

© 1996-2020 Amgen Inc. All Rights Reserved.